These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 22057933

  • 21. Treatment of Abnormalities of Potassium Homeostasis in CKD.
    Palmer BF, Clegg DJ.
    Adv Chronic Kidney Dis; 2017 Sep; 24(5):319-324. PubMed ID: 29031359
    [Abstract] [Full Text] [Related]

  • 22. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S, López-Mesa M, Gómez-Fernández P.
    Nefrologia (Engl Ed); 2021 Sep; 41(3):258-275. PubMed ID: 36166243
    [Abstract] [Full Text] [Related]

  • 23. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.
    Lazich I, Bakris GL.
    Semin Nephrol; 2014 May; 34(3):333-9. PubMed ID: 25016403
    [Abstract] [Full Text] [Related]

  • 24. Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice.
    De Nicola L, Di Lullo L, Paoletti E, Cupisti A, Bianchi S.
    J Nephrol; 2018 Oct; 31(5):653-664. PubMed ID: 29882199
    [Abstract] [Full Text] [Related]

  • 25. Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease.
    Oktaviono YH, Kusumawardhani N.
    Acta Med Indones; 2020 Jan; 52(1):74-79. PubMed ID: 32291375
    [Abstract] [Full Text] [Related]

  • 26. Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population.
    Wetmore JB, Yan H, Horne L, Peng Y, Gilbertson DT.
    Nephrol Dial Transplant; 2021 Apr 26; 36(5):826-839. PubMed ID: 31846025
    [Abstract] [Full Text] [Related]

  • 27. Discontinuation of RAAS Inhibition in Children with Advanced CKD.
    van den Belt SM, Heerspink HJL, Kirchner M, Gracchi V, Thurn-Valsassina D, Bayazit AK, Niemirska A, Canpolat N, Kaplan Bulut I, Azukaitis K, Duzova A, Bacchetta J, Shroff R, Paripovic D, Özçakar ZB, Fidan K, Erdogan H, Gellermann J, Wühl E, de Zeeuw D, Melk A, Querfeld U, Schaefer F.
    Clin J Am Soc Nephrol; 2020 May 07; 15(5):625-632. PubMed ID: 32253275
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Advances in treatment of hyperkalemia in chronic kidney disease.
    Sarafidis PA, Georgianos PI, Bakris GL.
    Expert Opin Pharmacother; 2015 May 07; 16(14):2205-15. PubMed ID: 26330193
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
    Jun M, Jardine MJ, Perkovic V, Pilard Q, Billot L, Rodgers A, Rogers K, Gallagher M.
    PLoS One; 2019 May 07; 14(3):e0213192. PubMed ID: 30845156
    [Abstract] [Full Text] [Related]

  • 34. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
    Rastogi A, Hanna RM, Mkrttchyan A, Khalid M, Yaqoob S, Shaffer K, Dhawan P, Nobakht N, Kamgar M, Goshtaseb R, Sarmosyan K, Gnarini M, Wassef O, Lerma E.
    Expert Rev Clin Pharmacol; 2021 Sep 07; 14(9):1055-1064. PubMed ID: 34227913
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators.
    JAMA; 2015 Jul 14; 314(2):151-61. PubMed ID: 26172895
    [Abstract] [Full Text] [Related]

  • 37. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G, Annis IE, Farley JF, Mahendraratnam N, Hickson RP, Stürmer T, Robinson JG.
    Pharmacotherapy; 2018 Jan 14; 38(1):29-41. PubMed ID: 29059475
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.